Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Survey of Commercial Biomolecules, Delimited to Pharmaceuticals and Medical Devices
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Show others and affiliations
2017 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Biologics — biomolecule-based therapeutics — are predicted to become the next generation of therapeutical drugs. The pharmaceutical industry is investing a great amount of money into research in this medical field, which shows the importance and the need of analyses regarding biological drugs. This report is a survey of commercial biologics in which the market and trends regarding the past, present and future are analysed. The results are based on a literature study limited to commercial biologics — either as chemical entities, as conjugates to another class of biomolecules or as medical devices. The market for biomolecule-based therapeutics and medical devices is predicted to flourish as the new generations of peptides, proteins, oligonucleotides, carbohydrates and lipids increase in both approvals and sales. The fact that scientists have gained a broader comprehension on a molecular level due to advanced technologies has resulted in biologics reaching clinical maturity. The optimized pharmacokinetic properties, greater specificity, and the increased therapeutic window have led to reduced side effects compared to traditional therapeutical alternatives. Due to new development approaches — peptidomimetics — the stability of peptides has shown to increase. This results in a huge market and development potential. The protein therapeutics market is the largest among biologics, and their subgroup — the monoclonal antibody-based therapeutics market — is the fastest growing. With a high growth rate of novel therapeutics in development, the market will continue to expand. Conjugated monoclonal antibodies (ADC) and GalNAc conjugates to small interfering RNA are just a few examples of high potential drugs that are expected to increase on the market and in clinical development. Oncology is the dominating therapeutic area, where great success has been observed in both clinical and pre-clinical studies. Lipid conjugates have proven to be efficient in the treatment of tumour cells and the cytotoxic ADC grant great hope for the biomolecule-based therapeutics market. The market is also expected to grow for establishing biologics; for example the increasing need of anticoagulants is predicted to double the Heparin market to 2023 and the demand for novel treatment alternatives opens market opportunities for Heparin biosimilars. The biological vaccine market is also predicted to grow together with biologics, as mutated animal-spread diseases increase in number.

Place, publisher, year, edition, pages
2017. , p. 59
Series
TVE ; 17009
Keywords [en]
Biologics
National Category
Engineering and Technology
Identifiers
URN: urn:nbn:se:uu:diva-324833OAI: oai:DiVA.org:uu-324833DiVA, id: diva2:1111803
External cooperation
SP Process Development
Subject / course
Chemistry
Educational program
Master Programme in Chemical Engineering
Presentation
2017-06-02, 13:50 (English)
Supervisors
Examiners
Available from: 2017-06-22 Created: 2017-06-19 Last updated: 2017-06-22Bibliographically approved

Open Access in DiVA

fulltext(915 kB)277 downloads
File information
File name FULLTEXT01.pdfFile size 915 kBChecksum SHA-512
533f15bb0c9306ed227a1344062593323f78d32d13dd3bb0dff798ab2405140c9fde550f6a9f97005aff434da79950379aed64f2e26dc29698b9a561b37dd8aa
Type fulltextMimetype application/pdf

By organisation
Department of Engineering Sciences
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
Total: 277 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 453 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf